Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a second-generation Gram-negative program, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. In addition, the company is involved in the discovery and development of additional antibiotics for the treatment of unmet medical needs, including multidrug-resistant Gram-negative bacteria. Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.